Key Takeaways
- Novo Nordisk shares surged more than 6% following FDA’s proposal to eliminate semaglutide, tirzepatide, and liraglutide from the 503B bulks compounding list
- The regulatory agency stated that outsourcing facilities have no clinical justification for compounding these medications
- The proposal enters a public comment phase lasting until June 29, 2026, prior to final determination
- NVO shares reached their strongest level in over 60 days, leading Copenhagen exchange gainers on Thursday
- Despite the rally, shares remain down over 16% for the year-to-date period
Shares of Novo Nordisk experienced a significant rally exceeding 6% during Thursday’s session following the FDA’s announcement of proposed restrictions on weight-loss drug compounding—a development that stands to directly favor the Danish pharmaceutical giant.
The Food and Drug Administration unveiled plans to eliminate semaglutide, tirzepatide, and liraglutide from the 503B bulks list. According to the agency’s statement, outsourcing facilities lack clinical justification for compounding these therapeutic agents.
The pharmaceutical company’s shares climbed to their strongest level in more than 60 days during Thursday’s trading and led all performers on the Copenhagen stock exchange.
NVO was changing hands around $42.38 during recent trading activity, significantly above both its 20-day moving average of $39.03 and 50-day moving average of $38.87.
Nonetheless, despite Thursday’s impressive gains, the stock continues trading beneath its 200-day moving average of $50.32 and maintains a year-to-date decline exceeding 16%.
The FDA has initiated a public feedback window extending through June 29, 2026, before issuing any conclusive determination on the regulatory proposal.
Challenges Facing Novo Nordisk
Novo Nordisk has encountered several obstacles in recent periods. Health Canada granted approval for the initial generic alternative to Ozempic within Canada, introducing fresh competitive pressures in a strategic market.
The company responded by implementing a share repurchase initiative. The firm has bought back approximately 13.4 million B-shares valued at 3.44 billion Danish kroner since February 2026, representing part of a 15 billion kroner, 12-month program.
Regarding developmental efforts, the pharmaceutical company has initiated a Phase 3 clinical trial for treating knee osteoarthritis and secured FDA fast-track status for a cardiovascular therapeutic.
First quarter 2026 financial results are scheduled for release on May 6.
Technical Analysis Perspective
Near-term momentum indicators show positive signals. The MACD indicator displays a buy signal while the RSI registers 54.73, indicating moderately bullish conditions.
However, the ADX measurement of 17.26 indicates the trend demonstrates limited strength. The Stochastic RSI generates a sell signal, suggesting potentially overbought territory.
Anton Kharitonov from Traders Union highlighted the delicate technical situation, noting that weak momentum measurements and overbought conditions indicate purchasing pressure may diminish rapidly. He identified the generic Ozempic threat in Canada as an additional risk factor.
Viktoras Karapetjanc, also affiliated with Traders Union, maintains a more optimistic outlook. He views the repurchase program and robust clinical development pipeline as fundamental supports for extended-term value, characterizing the recent decline as a possible springboard.
Market strategist Jainam Mehta identifies a tactical trading range spanning $40.78 to $43.23 as the critical zone. He indicated that a convincing breakout above or breakdown below these threshold levels would be necessary to alter the short-term risk profile.
The stock commenced Thursday’s session with a gap opening approximately $0.37 higher and accumulated gains of $1.94, representing a 4.80% intraday advance. Intraday volatility measured 2.47%.
